Recurrent Ovarian Cancers Respond to Cancer Vaccine After ‘Reprogramming’ With Decitabine


Key Points

  • Results of a phase I dose-escalation trial suggested that lower doses of decitabine administered prior to chemotherapy and the NY-ESO-1 vaccine are associated with improved clinical response in recurrent ovarian cancer.
  • Evidence of clinical benefit was seen in up to 60% of the patients with chemotherapy-resistant tumors.

Treatment with the drug decitabine prior to administration of chemotherapy and a cancer vaccine yielded clinical benefit for women with recurrent ovarian cancer, suggesting that this combinatorial chemoimmunotherapy may provide a new treatment option for patients with the disease, according to a study by Odunsi et al in Cancer Immunology Research.

A prerequisite for a patient’s immune system to recognize and attack his or her tumor is the presence of high levels of tumor antigens, proteins not normally found in the patient’s healthy cells. These proteins can be good targets for anticancer vaccines.

Targeting NY-ESO-1 Expression

“NY-ESO-1 is one of the few tumor antigens that have restricted expression in normal tissues but become aberrantly expressed in epithelial ovarian cancers and other solid tumors, so we focused on this antigen as the lead candidate for development of cancer immunotherapy,” said Kunle Odunsi, MD, PhD, principal investigator of the study, the M. Steven Piver Professor and Chair of the Department of Gynecologic Oncology, and Director of the Center for Immunotherapy at Roswell Park Cancer Institute in Buffalo, New York. “However, we observed that this antigen is not uniformly expressed by epithelial ovarian cancers, so our goal was to force the expression of NY-ESO-1 on ovarian cancer cells in order to allow the immune system to recognize and attack them.

“Expression of NY-ESO-1 is regulated by an epigenetic process called DNA methylation. Therefore, we tested the hypothesis that epigenetic reprogramming of NY-ESO-1 using the demethylating agent decitabine will augment vaccine-induced immunity,” he added. “Although clinical results were not a focus of this phase I trial, we saw evidence of clinical benefit in up to 60% of the patients with chemotherapy-resistant tumors. The combination of a demethylating agent, chemotherapy, and cancer vaccine may have enabled this remarkable effect.”

Phase I Study

Dr. Odunsi and colleagues conducted a phase I dose-escalation trial of decitabine, to which they recruited 12 women with epithelial ovarian cancer that had not responded to multiple lines of chemotherapy, with an estimated progression-free survival time of 3 months. All patients received decitabine on day 1, the chemotherapy drug doxorubicin on day 8, and the cancer vaccine (NY-ESO-1 protein with Montanide and GM-CSF) on day 15.

In preclinical analysis reported as part of this study, the investigators established the best sequence of drug administration: Decitabine was effective only when administered before chemotherapy, and it was ineffective if given after chemotherapy; vaccine administration was the last step.

The clinical trial participants were randomly assigned to receive a low, middle, or high dose of decitabine.


Of the 10 patients evaluable for clinical response, 5 had stable disease for up to 7.8 months, and 1 had a partial response with disease remission that lasted 5.8 months. All patients from the low- and middle-dose cohorts of decitabine showed clinical benefit, whereas only one-third of the patients who received the high dose showed benefit. These data suggest that lower doses of decitabine are associated with improved clinical response using this regimen. The treatment was well tolerated, and adverse events included hematologic side effects that were clinically manageable, according to Dr. Odunsi.

“One of the most remarkable results in terms of immune responses was that we were able to evoke what we call ‘antigen spreading,’” he said. “Although we immunized against a single target [NY-ES0-1], we analyzed and found that we were able to induce immune responses against three other antigens, against which we did not immunize.

“We propose that patients should actively seek these kinds of combination therapies. Even though the majority of these types of therapies are experimental at this point, there is enough scientific and clinical evidence to indicate that they are likely to be beneficial,” Dr. Odunsi added.

A phase II trial is being planned to test whether this treatment approach lengthens progression-free survival in patients with ovarian cancer.

Dr. Odunsi and Adam R. Karpf, of the University of Nebraska Medical Center, were the corresponding authors for the Cancer Immunology Research article.

This study was funded by the Ovarian Cancer Research Fund, the Roswell Park Alliance Foundation, a Cancer Vaccine Collaborative Grant, the Anna Maria Kellen Clinical Investigator Award, the National Cancer Institute, and Eisai Pharmaceuticals. Dr. Odunsi reported no potential conflicts of interest.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.